Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Trending
- Psychotherapist issues chilling warning of ‘absolute mess’ Trump will create
- Anti-Catholic rhetoric of 1960s is a lot like MAGA hate today: historian
- Psychologist exposes Trump falling asleep standing up in disaster speech
- Your car is being tracked 24/7 —and not for the reasons you think
- Trump chief squirms as affordability brags unravel on camera
- Morning Joe wonders if Trump has prediction market bets for GOP losing big
- Trump’s ultimate get-out-of-jail-free card
- Trump has reached his expiration date — and favorite excuse no longer works